/organisation/chugai-group-biodd-roche-tokyo-kanto-region-japan-2001-4020.html

Advertisement

Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81
Organisation › Details

Chugai (Group)

Chugai Pharmaceutical [Head Office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama] is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specialises in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area. In Japan, Chugai's research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and Ukima is conducting research for technology development for industrial production. Overseas, Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe. The consolidated revenue of Chugai in 2011 totalled 373.5 billion yen and the operating income was 62.4 billion yen. They are aiming at a consolidated revenue of 418.5 billion yen and operating income of 80 billion yen for 2012. *

 

Period Start 1990-01-01 existent
  Group Roche (Group)
Product Industry pharmaceutical
     
Region Region Tokyo
  Country Japan
  City 104-8301 Tokyo
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Debiopharm S.A.. (1/8/13). "Press Release: Chugai and Debiopharm Group Announce an Exclusive License Agreement for Anti-cancer Agent FF284 (Debio 1347)". Lausanne & Tokyo.
     
   
Record changed: 2019-06-09

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Roche (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80




» top